- Business Wire•yesterday
Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE™ (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
Synergy Pharmaceuticals Inc. announced today that the company has submitted a supplemental New Drug Application for TRULANCE™ for the treatment of adults with irritable bowel syndrome with constipation .
- Business Wire•14 days ago
Synergy Pharmaceuticals Inc. today announced that Marino Garcia, the company’s EVP and Chief Strategy Officer, will present a corporate update at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 11:30 a.m.
- Motley Fool•15 days ago
Is Synergy a buy on the post-approval dip?
SGYP : Summary for Synergy Pharmaceuticals, Inc. - Yahoo Finance
Synergy Pharmaceuticals Inc. (SGYP)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||4.65 x 500|
|Ask||4.85 x 2800|
|Day's Range||4.50 - 4.86|
|52 Week Range||2.60 - 7.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.96|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|